Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide

Molecular Imaging and Biology

Volumn 8, Issue 1, 2006, Pages 9-15

  Chen, Xiaoyuan ^a,c   Park, Ryan ^a   Khankaldyyan, Vazgen ^b   Gonzales Gomez, Ignacio ^b   Tohme, Michel ^a   Moats, Rex A ^b   Bading, James R ^a   Laug, Walter E ^b   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; F 18; Integrin; MicroPET; Molecular imaging; RGD

Indexed keywords

ALPHA INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; CD31 ANTIGEN; DIAGNOSTIC AGENT; FLUORINE; OLIGOPEPTIDE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG STRUCTURE; FOREBRAIN; GLIOBLASTOMA; HISTOPATHOLOGY; IMAGE ANALYSIS; INOCULATION; LONGITUDINAL STUDY; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOLOGICAL ANATOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOSENSITIVITY; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; CONFORMATION; HUMAN; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; METABOLISM; METHODOLOGY; NUDE MOUSE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; XENOGRAFT;

MUS MUSCULUS;

ANIMALS; ANTIGENS, CD31; BRAIN NEOPLASMS; FLUORINE RADIOISOTOPES; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MICE; MICE, NUDE; MOLECULAR CONFORMATION; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS;

EID: 33645803183     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-005-0024-1     Document Type: Article

References (33)

1. Jemal A, Tiwari RC, Murray T, et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8-29
2. Boiardi A, Silvani A, Pozzi A, et al. (1997) Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. J Neuro-Oncol 34:179-185
3. Puduvalli VK, Yung AW (1998) New frontiers in therapy of malignant gliomas. Forum 8:261-269
4. Puduvalli VK, Sawaya R (2000) Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors. J Neuro-Oncol 50:189-200
5. Taga T, Suzuki A, Gonzalez-Gomez I, et al. (2002) Alpha(v)-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98:690-697
6. MacDonald TJ, Taga T, Shimada H, et al. (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha-v integrin antagonist. Neurosurgery 48:151-157
7. Cristofanilli M, Charnsangavej C, Hortobagyi GN (2002) Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 1:415-426
8. 3-targeted nanoparticles. Magn Reson Med 44:433-439
9. 3-targeted magnetic resonance imaging. Nat Med 4:623-626
10. 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31:11-19
11. 18F-labeled RGD peptide: Initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 31:179-189
12. 64Cu-labeled RGD peptide. Bioconjug Chem 15:41-49
13. 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 31:1081-1089
14. 18F-labeled dimeric RGD peptide. Mol Imaging 3:96-104
15. 3 expression. J Nucl Med 45:1776-1783
16. 64Cu-labeled dimeric RGD Peptides. Mol Imaging Biol 6:350-359
17. 18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15:61-69
18. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785
19. Haubner R, Wester HJ, Burkhart F, et al. (2001) Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42:326-336
20. 3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 40:1061-1071
21. Janssen M, Oyen WJ, Massuger LF, et al. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 17:641-646
22. 3 integrin binding peptides in a nude mouse model. Cancer Res 62:6146-6151
23. Van Hagen PM, Breeman WA, Bernard HF, et al. (2000) Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy. Int J Cancer 90:186-198
24. 3. Circulation 108:336-341
25. Greenberg HS, Chandler WF, Sandler HM (1999) Brain Tumors (Contemporary Neurology Series, 54). New York: Oxford University Press.
26. Spence AM, Muzi M, Krohn KA (2002) Molecular imaging of regional brain tumor biology. J Cell Biochem 39(Suppl):25-35
27. Blouw B, Song H, Tihan T (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4:133-146
28. Holash J, Maisonpierre PC, Compton D, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998
29. Zagzag D, Amirnovin R, Greco MA, et al. (2000) Vascular apoptosis and involution in gliomas precede neovascularization: A novel concept for glioma growth and angiogenesis. Lab Invest 80:837-849
30. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410
31. 3 for angiogenesis. Science 264:569-571
32. Balaban RS, Hampshire VA (2001) Challenges in small animal noninvasive imaging. ILAR J 42:248-262
33. 18F]FDG uptake in mouse brain and heart using small animal PET. Nucl Med Biol 31:251-256